Strategy Shows Promise for Psoriasis Remission in Early Stud

The study is investigating whether high-dose IL-23 inhibition can target resident memory T cells and thereby induce long-term remission.

Related Keywords

United States , Portland , Oregon , Washington , American , Christopher Ritchlin , Andrew Blauvelt , Oregon Medical Research Center , National Psoriasis Foundation , University Of Rochesterny Medical Center , American Academy Of Dermatology , Drug Administration , Diseases Program Of The Accelerating Medicine Partnership , National Psoriasis , Psoriasis Area , Severity Index , American Academy , Medical Center , Immune Mediated Diseases Program , Accelerating Medicine Partnership , Psoriasis , Psoriatic Arthritis , Remission , Memory , Presidency , Biopsy , Tissue , Biologic Therapy , Arthritis , Oint Inflammation , Interleukin 2 , Sol 2 , Autoimmune Disease , Chronic Disease , Chronic Illness , Clinical Research , Clinical Trials , Linical Studies , Immunology , Interleukins , Lymph Nodes , Plaque Psoriasis , Severity Indices , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech ,